Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma (ACUFOCIN)

Randomised Clinical Trial of Acupuncture Plus Standard Care Versus Standard Care for Chemotherapy Induced Peripheral Neuropathy (CIPN)

The purpose of this study is to determine whether the addition of acupuncture to standard treatment reduces the level of chemotherapy induced peripheral neuropathy experienced by patients with breast cancer, multiple myeloma, gastrointestinal cancer or gynaecological cancer during or following treatment with neurotoxic chemotherapy.

Study Overview

• Status: Completed
• Conditions: Breast Cancer; Multiple Myeloma; Gastrointestinal Cancer; Gynaecological Cancer
• Intervention / Treatment: Procedure: Acupuncture; Other: Medication taken to manage the symptom burden of CIPN

Detailed Description

Chemotherapy Induced Peripheral Neuropathy (CIPN) is a significant clinical challenge for patients receiving specific chemotherapy regimen (e.g. taxanes and Bortezomib) and critically, if severe, CIPN can lead to the discontinuation of life prolonging treatment. CIPN poses a major problem for patient care as standard pharmacological treatments for CIPN have been found to be commonly ineffective and are often inadequate due to dosing complexities, delayed analgesic onset and side effects.

A service evaluation of the clinical data secured from using acupuncture to manage CIPN symptoms over a period of 18 months at The Christie National Health Service (NHS) Foundation Trust suggests it has the potential to provide an efficacious management tool to be used in addition to standard medication. This aim of this trial is to formally evaluate a 10 week course of acupuncture in the management of CIPN of grade 2 or above (symptoms experienced have a functional impact, graded in accordance with CTCAE v4.03), in patients with breast cancer, multiple myeloma, gastrointestinal cancer or gynaecological cancer.

This is a randomised, phase II, single-centre, controlled, open label trial . Patients meeting eligibility criteria will be randomised to receive acupuncture plus standard care (treatment arm) or standard care alone (control arm). Patients in both arms of the study will receive standard medication to manage symptoms of CIPN, as determined by a clinician in accordance with local trust policy. In addition to this, patients randomised to the treatment arm will receive 40 minute sessions of acupuncture on a weekly basis for 10 weeks. All patients will be offered acupuncture, to commence off trial at the end of their 10 week study period.

Outcome measures have been focused on assessing the impact of acupuncture on the patients' quality of life, symptom burden of CIPN and quantifying any effect size. There will also be a preliminary health economic evaluation of cost effectiveness. The data will be disseminated in addition to being used to establish whether a larger, multisite trial to confirm efficacy across all diagnostic groups, user acceptability and cost effectiveness is appropriate. This work will facilitate the team validating the study protocol and design as a template for a multicentre study and confirm user acceptability of the approach through additional qualitative data collected through focus group work at the completion of study participation.

• Study Type: Interventional
• Enrollment (Anticipated): 120
• Phase: Phase 2

Contacts and Locations

Study Locations

• United Kingdom
  • Manchester, United Kingdom, M20 4BX
    • The Christie NHS Foundation Trust
  • Oldham, United Kingdom, OL1 2JH
    • The Royal Oldham Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with breast cancer, multiple myeloma, gastrointestinal cancer or gynaecological cancer who are receiving or who have received neurotoxic chemotherapy treatment for their condition
• The capacity to understand the patient information sheet and the ability to give written informed consent
• Willingness and ability to comply with scheduled visits and study procedures, including the self-report QoL questionnaires and patient diaries
• Age ≥ 18 years; no upper age limit
• CIPN of ≥ Grade II (CTCAE v4.03)
• Platelet count of ≥ 30 x 10*9/L
• Neutrophil count of ≥ 0.5 x 10*9/L
• MYMOP2 score of their most troubling CIPN symptom ≥ 3

Exclusion Criteria:

• Patients who have previously received acupuncture for neuropathy
• Patients who have received acupuncture for any indication, other than neuropathy, within the previous 6 months
• Women who are pregnant or breast feeding
• Co-morbidity with a bleeding disorder
• Patients with an aversion to needles

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A: Standard care plus acupuncture; Medication taken to manage the symptom burden of CIPN plus acupuncture	Procedure: Acupuncture; 10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.; Other: Medication taken to manage the symptom burden of CIPN; Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.
Active Comparator: Arm B: Standard care alone; Medication taken to manage the symptom burden of CIPN	Other: Medication taken to manage the symptom burden of CIPN; Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Measure Yourself Medical Outcome Profile (MYMOP2) score of the most troubling symptom of CIPN	Assessed from patient completed questionnaire data: MYMOP2	Baseline, week 6 and week 10

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in grade of CIPN	Assessed by a clinician using a set of standardised questions, as a prompt, to assess the functional impact of CIPN. CIPN will be graded in accordance with CTCAE v4.03	Baseline, week 6 and week 10
Change in use of concomitant CIPN related medication	Includes change in dose and change in medication used to manage the symptom burden of CIPN.	Up to 10 weeks after baseline
Change in chemotherapy dosage		Up to 10 weeks after baseline
Pain related scores	Captured by the patient at baseline and then daily in the patient diary from week 1	Up to 10 weeks after baseline
Quality of life	Assessed from patient completed questionnaire data: European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) and the associated CIPN20 module	Baseline, week 6 and week 10
Acupuncture treatment compliance	Compliance to attending weekly acupuncture sessions	From week 1 (start of acupuncture treatment) until week 10
Preliminary health economic evaluation of cost effectiveness	Data will be captured from patient diaries completed continuously from week 1 until week 10 and from the patient notes. Patients will also complete the Euroqol (EQ-5D-5L) questionnaire at baseline, week 6 and week 10.	Up to 10 weeks after baseline
Uptake of the offer of acupuncture at 10 weeks	All patients will be offered acupuncture, to commence after the 10 week study period, at the 6 week visit. Acceptance of the offer will be captured at the 10 week visit.	10 weeks

Collaborators and Investigators

• Sponsor: The Christie NHS Foundation Trust
• Investigators: Study Chair: Andrew Wardley, The Christie NHS Foundation Trust

Study record dates

Study Major Dates

• Study Start (Actual): April 13, 2015
• Primary Completion (Actual): December 17, 2018
• Study Completion (Actual): December 17, 2018

Study Registration Dates

• First Submitted: October 22, 2014
• First Submitted That Met QC Criteria: October 23, 2014
• First Posted (Estimate): October 27, 2014

Study Record Updates

• Last Update Posted (Actual): January 31, 2019
• Last Update Submitted That Met QC Criteria: January 30, 2019
• Last Verified: January 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Cardiovascular Diseases; Vascular Diseases; Skin Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Immunoproliferative Disorders; Neoplasms by Site; Hematologic Diseases; Digestive System Neoplasms; Gastrointestinal Diseases; Breast Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Breast Neoplasms; Multiple Myeloma; Neoplasms, Plasma Cell; Gastrointestinal Neoplasms
• Other Study ID Numbers: 12_DOG06_165; PB-PG-0213-30129 (Other Grant/Funding Number: NIHR Research for Patient Benefit); CFTSp062 (Other Identifier: Sponsor)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO